IV-delivered therapy for canine OA advances toward FDA approvalMay 7, 2026A study of intravenous uterine-derived mesenchymal stromal cells (UMSCs) in dogs with “naturally occurring OA” reportedly shows improvements in pain and mobility, with no serious treatment-related adverse events.
SPONSORED CONTENTUncompromising renal + sensitivities care.Managing pain from canine OA doesn’t have to be complicated. Discover an approach that doesn’t just treat pain, but addresses inflammation, too. + Learn More
